Reach Us +44-1764910199
Redeveloping Drugs Based on Existing Patents | OMICS International | Abstract
ISSN: 2167-1079

Primary Healthcare: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Redeveloping Drugs Based on Existing Patents

Zhao XY1*, Diao TX1and Zeng YJ2

1Institute of Health Service and Medical Information, Beijing, China

2Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing 100022, China

*Corresponding Author:
Zhao XY
Institute of Health Service and Medical Information
Beijing, China
E-mail: [email protected]

Received date: March 02, 2016; Accepted date: August 02, 2016; Published date: August 09, 2016

Citation: Zhao XY, Diao TX, Zeng YJ (2016) Redeveloping Drugs Based on Existing Patents. Primary Health Care 6:233. doi:10.4172/2167-1079.1000233

Copyright: © 2016 Zhao XY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


With the advent of the era of knowledge economy and China’s join into WTO, the Problem of intellectual property rights of drug has become increasingly important to Pharmaceutical industry and even to all society. The Patent Protection is the most important part of intellectual property right of drug, which does not only act as a safe guard and stimulator to drug development, but also is a Powerful tool for drug development Providing comprehensive technology and law information. The paper analyzed some Pharmaceutical companies' strategies to develop new drug with Patent. An investigation of the U.S. Federal Trade Commission shows that, the pharmaceutical industry is more dependent on patents than any other industries; the industry prevents free competition, compensate R&D investment, and learn about new technical breakthroughs through patents. Chinese researchers have no strong awareness of using patent literatures, often neglecting acquisition and analysis of patent information. Therefore, the author summarized and analyzed current methods of how foreign pharmaceutical companies use patent information for drug development, to provide Chinese pharmaceutical companies with references on fully using patent resources to develop drugs